The alpha v integrin antagonists as novel anticancer agents: an update.
about
Visinin-like protein-1 is a potent inhibitor of cell adhesion and migration in squamous carcinoma cellsIn vivo bioluminescence tumor imaging of RGD peptide-modified adenoviral vector encoding firefly luciferase reporter gene.Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levelsBuilding a better TrapIntegrins: roles in cancer development and as treatment targets.Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation.Altered expression pattern of integrin alphavbeta3 correlates with actin cytoskeleton in primary cultures of human breast cancerAlpha-v integrins as therapeutic targets in oncology.The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy.The roles of αV integrins in lens EMT and posterior capsular opacification.Antiangiogenic anticancer strategy based on nanoparticulate systems.ADAM-15 disintegrin-like domain structure and function.Targeting nuclear factor-κB suppresses the negative effect of toll-like receptor 4 signaling on antimetastasis therapy based on targeting αvβ3.The minimum element of a synthetic peptide required to block prostate tumor cell migration.Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA.Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/Vitronectin interaction.The Rab4A effector protein Rabip4 is involved in migration of NIH 3T3 fibroblasts.
P2860
Q28237180-7000E85C-9C78-4803-BD15-E9A33C4FAF65Q34194326-5797EDE1-CE0C-4756-9B18-FAB7B3287034Q35062113-8B3BA445-BE88-45C4-8796-A690666F02D2Q35170252-0B9D0CCA-771D-4DF1-A48C-FF37153A5ED6Q35647842-17BE2FED-C731-46DB-9563-E90056653C3EQ35701298-2613E852-7DD1-4334-9BAE-C17F5BA54536Q36225128-DE88E07B-18C4-49DB-8377-F73925910D63Q37008623-C23A6E30-0E05-4A7A-B44E-CDEA9DFECD23Q37604903-744EC4A6-B9C7-4AA5-AB88-1C13ECDB6997Q37724031-3E6E9244-5973-47DA-89A9-6A5541B8C451Q37876400-181A68C8-A88A-4A23-998F-451248234ABFQ37954269-1A1A9F50-681B-4E6B-B005-60652C9F39F8Q39366006-E6E61969-B315-4900-BE48-D2D954BCEF16Q40208879-60B1D750-9851-4A0A-B097-07E8975F49B4Q40435095-332D4E86-C6E4-461A-BCF9-E275065D5D1DQ40637647-75A74E01-433C-4E39-881B-A9E485E18DF2Q42835173-311E4E60-6BB2-4D9B-9EC4-21B8784C756E
P2860
The alpha v integrin antagonists as novel anticancer agents: an update.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The alpha v integrin antagonists as novel anticancer agents: an update.
@ast
The alpha v integrin antagonists as novel anticancer agents: an update.
@en
type
label
The alpha v integrin antagonists as novel anticancer agents: an update.
@ast
The alpha v integrin antagonists as novel anticancer agents: an update.
@en
prefLabel
The alpha v integrin antagonists as novel anticancer agents: an update.
@ast
The alpha v integrin antagonists as novel anticancer agents: an update.
@en
P2093
P2860
P1476
The alpha v integrin antagonists as novel anticancer agents: an update.
@en
P2093
Andrew M Slee
Janet S Kerr
Shaker A Mousa
P2860
P304
P356
10.1517/13543784.11.12.1765
P407
P577
2002-12-01T00:00:00Z